For $275 million, Australia's CSL is buying from Novartis ($NVS) a network of vaccine manufacturing facilities, as well as a portfolio of products. The two announced the deal Monday. CSL, which has its own vaccinemaking facility in Australia, will now have plants in the U.K., Germany and the U.S. Novartis' $1 billion influenza vaccine manufacturing plant in Holly Springs, NC, is the first pandemic-ready site FDA-approved to make cell-culture influenza vaccines. The plant, supported in part by the U.S. Department of Health and Human Services as part of its pandemic preparedness program, started commercial production on Novartis' Flucelvax in June. Novartis, which has been losing money on its vaccine business, is taking a $1.1 billion charge on the sale. Story | More